295 related articles for article (PubMed ID: 33334611)
1. Hyperprogressive disease in patients receiving immune checkpoint inhibitors.
Zhang H; Fang X; Li D; Yang M; Yu L; Ding Y; Shen H; Yuan Y
Curr Probl Cancer; 2021 Jun; 45(3):100688. PubMed ID: 33334611
[TBL] [Abstract][Full Text] [Related]
2. Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer.
Chen S; Gou M; Yan H; Fan M; Pan Y; Fan R; Qian N; Dai G
Dis Markers; 2021; 2021():6639366. PubMed ID: 34239621
[TBL] [Abstract][Full Text] [Related]
3. Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting.
Kanjanapan Y; Guduguntla G; Varikara AK; Szajer J; Yip D; Cockburn J; Fadia M
Technol Cancer Res Treat; 2023; 22():15330338231209129. PubMed ID: 37885403
[No Abstract] [Full Text] [Related]
4. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
Matos I; Martin-Liberal J; García-Ruiz A; Hierro C; Ochoa de Olza M; Viaplana C; Azaro A; Vieito M; Braña I; Mur G; Ros J; Mateos J; Villacampa G; Berché R; Oliveira M; Alsina M; Elez E; Oaknin A; Muñoz-Couselo E; Carles J; Felip E; Rodón J; Tabernero J; Dienstmann R; Perez-Lopez R; Garralda E
Clin Cancer Res; 2020 Apr; 26(8):1846-1855. PubMed ID: 31757877
[TBL] [Abstract][Full Text] [Related]
5. The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy.
Wang X; Wang F; Zhong M; Yarden Y; Fu L
Mol Cancer; 2020 May; 19(1):81. PubMed ID: 32359357
[TBL] [Abstract][Full Text] [Related]
6. Atypical patterns of response and progression in the era of immunotherapy combinations.
Ferrara R; Matos I
Future Oncol; 2020 Aug; 16(23):1707-1713. PubMed ID: 32687405
[TBL] [Abstract][Full Text] [Related]
7. Hyperprogressive disease: A distinct pattern of progression to immune checkpoint inhibitors.
Toki MI; Syrigos N; Syrigos K
Int J Cancer; 2021 Jul; 149(2):277-286. PubMed ID: 33300601
[TBL] [Abstract][Full Text] [Related]
8. Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?
Adashek JJ; Subbiah IM; Matos I; Garralda E; Menta AK; Ganeshan DM; Subbiah V
Trends Cancer; 2020 Mar; 6(3):181-191. PubMed ID: 32101722
[TBL] [Abstract][Full Text] [Related]
9. How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
Denis M; Duruisseaux M; Brevet M; Dumontet C
Front Immunol; 2020; 11():492. PubMed ID: 32265935
[TBL] [Abstract][Full Text] [Related]
10. Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Park HJ; Kim KW; Won SE; Yoon S; Chae YK; Tirumani SH; Ramaiya NH
JAMA Netw Open; 2021 Mar; 4(3):e211136. PubMed ID: 33760090
[TBL] [Abstract][Full Text] [Related]
11. Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies.
Zhao LP; Hu JH; Hu D; Wang HJ; Huang CG; Luo RH; Zhou ZH; Huang XY; Xie T; Lou JS
Biomed Pharmacother; 2022 Jun; 150():112949. PubMed ID: 35447545
[TBL] [Abstract][Full Text] [Related]
12. Current Understanding and Future Perspectives on Hyperprogressive Disease Highlight the Tumor Microenvironment.
Li M; Zhong X; Du F; Wu X; Li M; Chen Y; Zhao Y; Shen J; Yang Z; Xiao Z
J Clin Pharmacol; 2022 Sep; 62(9):1059-1078. PubMed ID: 35303368
[TBL] [Abstract][Full Text] [Related]
13. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
[TBL] [Abstract][Full Text] [Related]
14. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
Feng D; Guan Y; Liu M; He S; Zhao W; Yin B; Liang J; Li Y; Wang J
Front Immunol; 2021; 12():608292. PubMed ID: 34135884
[TBL] [Abstract][Full Text] [Related]
15. Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature.
Grecea M; Marabelle A; Ammari S; Massard C; Champiat S
Oncologist; 2020 May; 25(5):369-374. PubMed ID: 32091646
[TBL] [Abstract][Full Text] [Related]
16. Regulatory T cells as crucial trigger and potential target for hyperprogressive disease subsequent to PD-1/PD-L1 blockade for cancer treatment.
Ren Z; Yang K; Zhu L; Yin D; Zhou Y
Int Immunopharmacol; 2024 May; 132():111934. PubMed ID: 38574701
[TBL] [Abstract][Full Text] [Related]
17. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
Hwang I; Park I; Yoon SK; Lee JL
Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
[TBL] [Abstract][Full Text] [Related]
18. Redefining Clinical Hyperprogression: The Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy.
Djunadi TA; Oh Y; Lee J; Yu J; Chung LI; Lee Y; Kim L; Hong T; Lee S; Shah Z; Park JH; Yoon SM; Chae YK
Clin Lung Cancer; 2024 Jun; 25(4):365-375.e14. PubMed ID: 38644088
[TBL] [Abstract][Full Text] [Related]
19. Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy.
Wei Z; Zhang Y
Cells; 2022 May; 11(11):. PubMed ID: 35681453
[TBL] [Abstract][Full Text] [Related]
20. Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs).
Liu J; Wu Q; Wu S; Xie X
Clin Transl Oncol; 2021 Sep; 23(9):1782-1793. PubMed ID: 33847923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
